Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.
about
FGF-21 as a novel metabolic regulator.Molecular basis for negative regulation of the glucagon receptorFrom Beta cell replacement to beta cell regeneration: implications for antidiabetic therapyEnergy metabolism in the liverIncreased lipolysis and energy expenditure in a mouse model with severely impaired glucagon secretionThe glucagon receptor is required for the adaptive metabolic response to fastingResponse to comments on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:25A genome-wide siRNA screen to identify modulators of insulin sensitivity and gluconeogenesisPolyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes.Ingestion of a moderate high-sucrose diet results in glucose intolerance with reduced liver glucokinase activity and impaired glucagon-like peptide-1 secretionPancreatic neuroendocrine tumors in glucagon receptor-deficient mice.Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice.Proglucagon-derived peptides: mechanisms of action and therapeutic potential.Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonistHuman monoclonal antibodies against glucagon receptor improve glucose homeostasis by suppression of hepatic glucose output in diet-induced obese mice.Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in miceAblation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturationRecent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes MellitusA novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor.CrbpI modulates glucose homeostasis and pancreas 9-cis-retinoic acid concentrations.Absence of the glucagon-like peptide-1 receptor does not affect the metabolic phenotype of mice with liver-specific G(s)α deficiency.A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design.Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in miceAn AlphaScreen Assay for the Discovery of Synthetic Chemical Inhibitors of Glucagon ProductionProspects of antisense oligodeoxynucleotides to alleviate renal ischaemia-reperfusion injury.Regulation of mouse intestinal L cell progenitors proliferation by the glucagon family of peptides.Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin SensitivityGlucagon as a target for the treatment of Type 2 diabetes.Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon?Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promiseEctopic expression of GIP in pancreatic β-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides.Biologic actions and therapeutic potential of the proglucagon-derived peptides.Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor.cAMP-responsive element-binding protein (CREB)-regulated transcription coactivator 2 (CRTC2) promotes glucagon clearance and hepatic amino acid catabolism to regulate glucose homeostasis.Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist.Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocinCurrent insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes.Antisense technology: an emerging platform for cardiovascular disease therapeutics.Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.
P2860
Q24523933-43E97040-3060-4126-9185-F29FDC628115Q24604062-EBE72E18-A0E4-4AA6-8D7E-07711D3CA7D8Q26864024-FA770BF6-0918-4DF6-8D39-D539D93E6E5AQ26996783-1B269670-3E28-48BA-BD65-273FA0822320Q28477671-D78A86F0-A871-451B-98E2-F48AE619B861Q28594780-1A403B52-4C35-4B36-9E9E-4CB565CDA005Q28679307-E8857A61-B97E-457B-82F8-C2B20FB113BAQ28730046-60F59976-147E-44AC-BD3E-B17093416C73Q30502199-5DF753A4-C97C-4BB4-B682-22F0BC6A9FC7Q33603296-BA2AAF85-5B30-4714-B252-5F9C76EB53F3Q33997146-983B1CBC-BE3E-4BEB-9C9F-2DC82229E3F4Q34132179-7DCA6F9D-FDE9-41ED-B2DD-FFF4DC86B6E0Q34452524-84174517-0621-4B08-B9C1-53F2FA41B388Q34490178-8F1CEA3C-2107-4BB1-A5BC-1FF9488B8965Q34506664-FE34D14A-3E83-4C2D-8068-95CA215972D4Q34526968-49CACE6C-1396-4728-A295-E9D418B3A3B5Q34871133-D6D31767-19AA-42B6-AE19-A64211908927Q35062439-14B98A94-C7AD-4658-B4B9-6A312F6C89EDQ35138670-6A90CAB0-8B75-43BC-AC4F-FE2180711674Q35139983-66F32A45-0B31-4428-838D-DA6A2A0ACB9EQ35175696-7144A9FF-41FF-4922-8186-564B1AE7C61BQ35318135-996A3546-EDEE-4EE1-8EDD-727361D5A56AQ35762651-25B60576-B7AE-4BB6-A3C6-627BCB298D45Q35780266-B8BE4E55-B2BD-4A33-AE18-D4CFC4FAA2C5Q35871063-33443B85-D398-416A-B49A-B9276DAF1AECQ35967291-1D26D562-6A3E-40AB-AD94-142F86E373D2Q36049852-D36E238E-A4FF-453C-A738-0294FBFF1CFCQ36104668-94BEDCB3-F3F2-4BDE-85B2-DE1FE51D0730Q36158732-DEDCDD88-39B7-430B-99CC-5F094934FF26Q36192991-C3729B62-B79E-40BD-8008-A162FC3F8A14Q36514704-3A2B51F5-0E1C-45D3-AB84-ADA5BE775F6AQ36560559-B40E98F0-0290-41A4-B5F0-5CC7FDCDF1E2Q36575421-BB1BBE3F-BBE1-4ACC-B5EE-81AC08E8E5D8Q36720548-809487C5-7B73-428E-A134-3E8D8E0AA0C7Q36890766-1358C9F1-4AD7-42D7-9DF4-29079B7202A6Q36913461-EC7D9ABD-95FA-41D6-B6EA-B23EA44CFC5CQ36990110-B6B98F49-7933-488C-8949-A3A3D6B2D22FQ37260041-DADD8209-326E-45CC-B9B4-8ADC8C07F4B5Q37337608-7151055B-3563-4145-8C1D-EA8D2DB6E09BQ37360316-C28B9F9C-658D-4261-A50D-490EE86C0A57
P2860
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Hepatic and glucagon-like pept ...... se oligonucleotide inhibitors.
@ast
Hepatic and glucagon-like pept ...... se oligonucleotide inhibitors.
@en
Hepatic and glucagon-like pept ...... se oligonucleotide inhibitors.
@nl
type
label
Hepatic and glucagon-like pept ...... se oligonucleotide inhibitors.
@ast
Hepatic and glucagon-like pept ...... se oligonucleotide inhibitors.
@en
Hepatic and glucagon-like pept ...... se oligonucleotide inhibitors.
@nl
prefLabel
Hepatic and glucagon-like pept ...... se oligonucleotide inhibitors.
@ast
Hepatic and glucagon-like pept ...... se oligonucleotide inhibitors.
@en
Hepatic and glucagon-like pept ...... se oligonucleotide inhibitors.
@nl
P2093
P2860
P356
P1476
Hepatic and glucagon-like pept ...... se oligonucleotide inhibitors.
@en
P2093
Aaron D Showalter
Achim Raap
Angela M Siesky
Brett P Monia
Brian R Berridge
David K B Monteith
Diane M Bodenmiller
Hong Yan Zhang
Jesper Gromada
P2860
P304
P356
10.1172/JCI20911
P407
P577
2004-06-01T00:00:00Z